AngioDynamics Raises FY2026 Net Sales and Adjusted EBITDA Guidance at J.P. Morgan Healthcare Conference
Summary
AngioDynamics, Inc. updated its fiscal year 2026 financial guidance, increasing projections for net sales and adjusted EBITDA, while presenting its strategic vision and product pipeline at the J.P. Morgan 44th Annual Healthcare Conference.
Key Events
-
Raised FY2026 Net Sales Guidance
The company increased its fiscal year 2026 net sales guidance from $308-$313 million to $312-$314 million.
-
Increased Adjusted EBITDA Outlook
Adjusted EBITDA guidance for FY2026 was raised from $6.0-$10.0 million to $8.0-$10.0 million.
-
Strategic Business Update
The CEO presented a comprehensive overview of the company's MedTech platforms, product pipeline, and clinical data at the J.P. Morgan 44th Annual Healthcare Conference.
-
Strong Financial Position
AngioDynamics reported $41.6 million in cash as of November 30, 2025, and zero debt, providing financial flexibility.
Analysis
AngioDynamics, Inc.'s decision to raise its full-year 2026 net sales and adjusted EBITDA guidance signals improved operational performance and a more optimistic outlook. This update, delivered at a major healthcare conference, provides investors with a positive indication of the company's trajectory and reinforces confidence in its MedTech platforms and strategic initiatives. The presentation also highlighted a strong balance sheet with zero debt, supporting future growth and innovation.
At the time of this filing, ANGO was trading at $10.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $415.1M. The 52-week trading range was $8.27 to $13.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.